Nature Medicine· Vidyalakshmi Chandramohan·· 2026-10-16AI 评分58
复发性胶质瘤EGFR靶向抗体-毒素偶联物I期试验
EGFR-targeted antibody−toxin conjugate in recurrent glioma: a phase 1 trial
AI 导读
针对复发性恶性胶质瘤的D2C7-ATC抗体-毒素偶联物I期试验结果初步呈现了令人鼓舞的安全性和疗效信号。研究还观察到患者样本中存在肿瘤内和系统性免疫激活。
正文
Nature Medicine, Published online: 16 October 2026; doi:10.1038/s41591-026-04715-w
Results of a phase 1 trial of the antibody−toxin conjugate D2C7-ATC targeting EGFR/EGFRvIII in patients with recurrent malignant glioma show encouraging safety and efficacy signals, with translational analyses of patient samples indicating intratumoral and systemic immune activation.
来源:Nature Medicine · nature.com